amdoxovir

Small moleculeexperimental

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi and C.K. Chu and developed by RFS Pharma. — Wikipedia

Clinical trial activity

5 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
5
Phase 3
0
Phase 4
0

Earliest trial started Feb 20, 2002 (NCT00031044)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Nc1nc(N)c2ncn([C@H]3CO[C@@H](CO)O3)c2n1
Mol. weight
252.23 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2,6-diaminopurine dioxolane
  • 4-(2,6-diamino-9h-purin-9-yl)-1,3,-dioxolane-2-methanol
  • amdoxovir
  • amdoxovir
  • amdoxovir
  • amdoxovir
  • dapd
  • dapd
  • (-)-dapd
  • (-)-dapd

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01738555Phase 2Apr 1, 2013RFS Pharma
NCT01737359Phase 2Dec 1, 2012RFS Pharma
NCT00432016Phase 1/Phase 2 (Phase 2)Feb 1, 2007Hospital Privado Modelo, RFS Pharma
NCT00038272Phase 2May 29, 2002National Institute of Allergy and Infectious Diseases (NIAID), The University of Texas, Dallas
NCT00031044Phase 1/Phase 2 (Phase 2)Feb 20, 2002Columbia University, Harvard University, National Institute of Allergy and Infectious Diseases (NIAID)
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
RFS PharmaFor profit3312007
National Institute of Allergy and Infectious Diseases (NIAID)Government2212002
Columbia UniversityAcademic/Hospital1012002
Harvard UniversityAcademic/Hospital1012002
Hospital Privado ModeloAcademic/Hospital1012007
The University of Texas, DallasAcademic/Hospital1012002
6 organizations
Page 1 / 1